Table 3.
All-cause mortality outcomes.
| First Author, Year, Country |
Population Studied | Effect Size Estimated for BZD with OAT | 95% Confidence Interval | Other Outcomes |
|---|---|---|---|---|
| Abrahamsson, 2017, Sweden [18] |
OAT population (n = 4501) |
Significant increase HR 1.75 |
1.28–2.39 | |
| Bakker, 2017, UK [19] | GP practice OAT Case note review (n = 278) |
ACM lower for brief/occasional prescribing compared to BZD maintenance or no BZD | ||
| MacLeod, 2019, UK [24] |
Primary care OAT, England (n = 12,118) |
Significant increase HR 1.87 |
1.55–2.25 | |
| Park, 2020, USA [28] |
Buprenorphine OAT (n = 63,345) | Significant increase HR 1.9 |
1.48–2.44 | Overdose (HR 1.9) |
| Sharma, 2020, Canada [31] |
Population opioid prescriptions (n = 179,805) | Significant increase OR 1.9 Males OR 2.09 Female OR 1.73 |
1.76–2.05 1.87–2.33 1.56–1.92 |
BZD = benzodiazepine; HR: hazard ratio.